{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:16:35Z","timestamp":1791314195507,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,17]]},"DOI":"10.7759\/cureus.16445","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T21:22:02Z","timestamp":1626556922000},"source":"Crossref","is-referenced-by-count":15,"title":["Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies"],"prefix":"10.7759","author":[{"given":"Vildan","family":"Gursoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahir","family":"Ozkalemkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Ozkocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Serenli yegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ethem Pinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"Ener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halis","family":"Akal\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Kazak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridvan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alparslan","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1406.019","article-title":"Amphotericin B and coccidioidomycosis","volume":"1111","author":"Johnson RH","year":"2007","unstructured":"Johnson RH, Einstein HE. Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci. 2007, 1111:434-41. 10.1196\/annals.1406.019","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.2.167","article-title":"Liposomal amphotericin B: clinical experience and perspectives","volume":"3","author":"Gibbs WJ","year":"2005","unstructured":"Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther. 2005, 3:167-81. 10.1586\/14787210.3.2.167","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref3","article-title":"Amphotericin B: time for a new\" gold standard\"","volume":"415","author":"Ostrosky-Zeichner L","year":"2003","unstructured":"Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new\" gold standard\". Clin Infect Dis. 2003, 415:25.","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_b.27","article-title":"Amphotericin B: an introduction","volume":"28 Suppl B","author":"Warnock DW","year":"1991","unstructured":"Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother. 1991, 28 Suppl B:27-38. 10.1093\/jac\/28.suppl_b.27","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie EJ","year":"1996","unstructured":"Anaissie EJ, Darouiche RO, Abi-Said D, et al.. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996, 23:964-72. 10.1093\/clinids\/23.5.964","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn R","year":"2009","unstructured":"Laniado-Labor\u00edn R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009, 26:223-7. 10.1016\/j.riam.2009.06.003","journal-title":"Rev Iberoam Micol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1472-1","article-title":"Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity","volume":"69","author":"Karimzadeh I","year":"2013","unstructured":"Karimzadeh I, Khalili H, Farsaei S, Dashti-Khavidaki S, Sagheb MM. Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol. 2013, 69:1351-68. 10.1007\/s00228-013-1472-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh TJ","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, et al.. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999, 340:764-71. 10.1056\/NEJM199903113401004","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.81","article-title":"Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"49 Suppl 1","author":"Cagnoni PJ","year":"2002","unstructured":"Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother. 2002, 49 Suppl 1:81-6. 10.1093\/jac\/49.suppl_1.81","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49 Suppl 1","author":"Deray G","year":"2002","unstructured":"Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002, 49 Suppl 1:37-41. 10.1093\/jac\/49.suppl_1.37","journal-title":"J Antimicrob Chemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.229","article-title":"Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents","volume":"41","author":"Zager RA","year":"1992","unstructured":"Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int. 1992, 41:1588-94. 10.1038\/ki.1992.229","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis290","article-title":"Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis","volume":"54","author":"Mistro S","year":"2012","unstructured":"Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badar\u00f3 R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012, 54:1774-7. 10.1093\/cid\/cis290","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05782-z","article-title":"Conventional amphotericin B should remain in the armamentarium as a cheap and efficient waiting solution","volume":"46","author":"Roux D","year":"2020","unstructured":"Roux D, Gaudry S, Dreyfuss D. Conventional amphotericin B should remain in the armamentarium as a cheap and efficient waiting solution. Intensive Care Med. 2020, 46:558-9. 10.1007\/s00134-019-05782-z","journal-title":"Intensive Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. The","volume":"111","author":"Harbarth S","year":"2001","unstructured":"Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. The. Am J Med. 2001, 111:528-34. 10.1016\/S0002-9343(01)00928-7","journal-title":"Am J Med"},{"key":"ref15","article-title":"A drug utilization evaluation study of amphotericin B in neutropenic patients in a teaching hospital in Iran","volume":"11","author":"Tavakoli-Ardakani M","year":"2012","unstructured":"Tavakoli-Ardakani M, Eshraghi A, Hajhossein Talasaz A, Salamzadeh J. A drug utilization evaluation study of amphotericin B in neutropenic patients in a teaching hospital in Iran. Iran J Pharm Res. 2012, 11:151-6.","journal-title":"Iran J Pharm Res"},{"key":"ref16","article-title":"Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome","volume":"51","author":"Khalili H","year":"2013","unstructured":"Khalili H, Bairami S, Kargar M. Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Medica Iranica. 2013, 51:871-8.","journal-title":"Acta Medica Iranica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80612-6","article-title":"Risk factors for amphotericin B-associated nephrotoxicity","volume":"87","author":"Fisher MA","year":"1989","unstructured":"Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med. 1989, 87:547-52. 10.1016\/S0002-9343(89)80612-6","journal-title":"Am J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity","volume":"43","author":"Luber AD","year":"1999","unstructured":"Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999, 43:267-71. 10.1093\/jac\/43.2.267","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1177\/0091270007301799","article-title":"Pharmacological risk factors for amphotericin B nephrotoxicity in children","volume":"47","author":"Goldman RD","year":"2007","unstructured":"Goldman RD, Ong M, Wolpin J, Doyle J, Parshuram C, Koren G. Pharmacological risk factors for amphotericin B nephrotoxicity in children. J Clin Pharmacol. 2007, 47:1049-55.","journal-title":"J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00948.x","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates DW","year":"2001","unstructured":"Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Platt R. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001, 60:1452-9. 10.1046\/j.1523-1755.2001.00948.x","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90353-4","article-title":"Amphotericin B nephrotoxicity in humans decreased by salt repletion","volume":"75","author":"Heidemann HT","year":"1983","unstructured":"Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med. 1983, 75:476-81. 10.1016\/0002-9343(83)90353-4","journal-title":"Am J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370030191038","article-title":"Recurrent reversible acute renal failure from amphotericin","volume":"147","author":"Sacks P","year":"1987","unstructured":"Sacks P, Fellner SK. Recurrent reversible acute renal failure from amphotericin. Arch Int Med. 1987, 147:593-5. 10.1001\/archinte.1987.00370030191038","journal-title":"Arch Int Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.721775","article-title":"Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?","volume":"11","author":"Karimzadeh I","year":"2012","unstructured":"Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?. Expert Opin Drug Saf. 2012, 11:969-83. 10.1517\/14740338.2012.721775","journal-title":"Expert Opin Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden MM","year":"2003","unstructured":"Roden MM, Nelson LD, Knudsen TA, et al.. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003, 36:1213-20. 10.1086\/374553","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19127","article-title":"Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia","volume":"34","author":"Wazny LD","year":"2000","unstructured":"Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother. 2000, 34:94-7. 10.1345\/aph.19127","journal-title":"Ann Pharmacother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.39581","article-title":"Frequency and associated factors of amphotericin b nephrotoxicity in hospitalized patients in hematology-oncology wards in the Southwest of Iran","volume":"8","author":"Karimzadeh I","year":"2016","unstructured":"Karimzadeh I, Heydari M, Ramzi M, Sagheb MM. Frequency and associated factors of amphotericin b nephrotoxicity in hospitalized patients in hematology-oncology wards in the Southwest of Iran. Nephrourol Mon. 2016, 8:e39581. 10.5812\/numonthly.39581","journal-title":"Nephrourol Mon"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90106-2","article-title":"Renal magnesium wasting associated with amphotericin B therapy","volume":"77","author":"Barton C","year":"1984","unstructured":"Barton C, Pahl M, Vaziri N, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med. 1984, 77:471-4. 10.1016\/0002-9343(84)90106-2","journal-title":"Am J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528090-00003","article-title":"Drug-induced hypomagnesaemia: scope and management","volume":"28","author":"Atsmon J","year":"2005","unstructured":"Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf. 2005, 28:763-88. 10.2165\/00002018-200528090-00003","journal-title":"Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18181","article-title":"Hepatotoxicity possibly caused by amphotericin B","volume":"33","author":"Gill J","year":"1999","unstructured":"Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother. 1999, 33:683-5. 10.1345\/aph.18181","journal-title":"Ann Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.6.928","article-title":"Abnormalities in liver enzymes during simultaneous therapy with itraconazole and amphotericin B in leukaemic patients","volume":"45","author":"Persat F","year":"2000","unstructured":"Persat F, Schwartzbrod PE, Troncy J, Timour Q, Maul A, Piens MA, Picot S. Abnormalities in liver enzymes during simultaneous therapy with itraconazole and amphotericin B in leukaemic patients. J Antimicrob Chemother. 2000, 45:928-9. 10.1093\/jac\/45.6.928","journal-title":"J Antimicrob Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62752-conventional-amphotericin-b-associated-nephrotoxicity-in-patients-with-hematologic-malignancies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:13Z","timestamp":1707507133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62752-conventional-amphotericin-b-associated-nephrotoxicity-in-patients-with-hematologic-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.16445","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,17]]}}}